Crystal Lake, Illinois — December 18, 2025 — Leads & Copy — Aptar Group, Inc.’s Bidose Liquid Nasal Spray System is being used to deliver the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST, developed by Milestone® Pharmaceuticals Inc., has been approved by the U.S. Food and Drug Administration (FDA) for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
This marks the first time Aptar has combined dual Bidose delivery systems within a consumer-friendly two-pack container.
Milestone Pharmaceuticals received FDA approval for CARDAMYST to convert acute symptomatic episodes of PSVT, commonly called SVT, to sinus rhythm in adults.
PSVT affects an estimated two million people in the United States. The condition is characterized by sudden, rapid heartbeats, often exceeding 150 to 200 beats per minute. This results in an estimated 140,000 to 525,000 Emergency Department visits and 40,000 to 120,000 inpatient hospitalizations in the U.S. annually.
CARDAMYST is designed for ease of use and portability. Aptar CSP Technologies collaborated with Milestone Pharmaceuticals to create a custom-designed, patient-friendly polypropylene container closure system with a fully integrated cap for CARDAMYST. The dual-container system securely houses two Bidose delivery mechanisms and is designed to prevent accidental activation or dropping while promoting reliability.
Aptar Pharma President Gael Touya said the approval highlights the expansion of Aptar’s drug delivery solutions across therapeutic areas and the increasing demand for nasal drug delivery. He added that the company is pleased that its Bidose nasal system, along with the protective dual-container system, is now available for patients in another therapeutic area.
Aptar Pharma Prescription President Alex Theodorakis noted that the successful outcome, after years of collaboration with Milestone, demonstrates the company’s ability to support customers in developing and launching complex treatments with user-friendly and reliable systems.
Milestone Pharmaceuticals President and CEO Joseph Oliveto said Aptar has been an essential partner in developing and delivering a novel treatment for PSVT that addresses a significant unmet need. He added that the company is proud to partner with a company that shares its commitment to innovation and quality and looks forward to working together to provide CARDAMYST to patients.
Aptar’s Bidose (BDS) and Unidose (UDS) systems are designed for intuitive and reliable intranasal administration, meeting strict U.S. FDA quality standards. These platforms offer effective single or two-shot intranasal delivery for various medicines, supporting pharmaceutical partners in developing emergency use treatments.
This innovative treatment for PSVT represents a Combination Product submission, benefiting from Aptar Pharma’s Drug Services offering, which includes stage-specific development packages. Aptar’s Regulatory Affairs experts and analytical scientists assist customers in addressing regulatory needs to expedite approval.
Aptar is a global leader in drug and consumer product dosing, dispensing, and protection technologies, serving markets including pharmaceutical, beauty, food, beverage, personal care, and home care. Aptar is headquartered in Crystal Lake, Illinois, and has over 13,000 employees in 20 countries.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, approved by the FDA for converting acute symptomatic episodes of PSVT to sinus rhythm in adults. Etripamil is also in development for treating symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular rate, or AFib-RVR.
Contact:
Gael Touya, President of Aptar Pharma
Alex Theodorakis, President, Aptar Pharma Prescription
Joseph Oliveto, President and CEO, Milestone Pharmaceuticals.
Source: Aptar
